E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
FULLY RESECTED STAGE III COLON CANCER |
NEOPLASIA RESECATA DEL COLON IN STADIO III |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10010034 |
E.1.2 | Term | Colorectal cancer stage III |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of the study is to assess and to compare the disease free survival curves |
Intervallo libero da recidiva (Desease Free Survival) |
|
E.2.2 | Secondary objectives of the trial |
3-year disease-free survival
Overall Survival
5-year overall Survival
Treatment compliance
Identification of prognostic factors
Safety
Markers predictive for relapse and/or treatment efficacy |
- Intervallo libero da recidiva a 3 anni
- Sopravvivenza totale
- Compliance al trattamento
- Tasso di sopravvivenza a 5 anni
- Identificazione dei fattori prognostici
- Sicurezza
- Ricerca translazionale volta a valutare i fattori biologici (marcatori) predittivi di recidiva e/o di efficacia del trattamento. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
PHARMACOGENETIC: Vers: Date: Title: Objectives:
|
FARMACOGENETICA: Vers: Data: Titolo:patterns of expression and activation status of the EGFR Obiettivi:
|
|
E.3 | Principal inclusion criteria |
Inpatient or outpatient ≥ 18 and < 75 years of age
Pathologically confirmed stage III colon adenocarcinoma, regardless of the EGFR status, as following
Curative R0 resection performed within not less than 28 and not more than 56 days prior to randomization
No prior chemotherapy
No prior abdominal or pelvic irradiation
WHO performance status: 0 or 1
Life expectancy of ≥ 5 years
Patients with childbearing potential should use effective contraception during the study and the following 6 months
White blood cell count ≥ 3 x 109/L with neutrophils ≥ 1.5 x 109/L, platelet count ≥ 100 x 109/L, hemoglobin ≥ 9 g/dL (5,6 mmol/l)
Total bilirubin < o pari a 1.5 x ULN (upper limit of normal)
ASAT and ALAT < o pari a 2.5 x ULN
Alkaline phosphatase < o pari a 1.5 x ULN
Serum creatinine < o pari a 1.5 x ULN
Carcinoembryogenic antigen (CEA) < o pari a 1.5 x ULN after surgery (during screening period)
Signed written informed consent obtained prior to any study specific screening procedures |
- Eta' > o pari 18 e < 75
- Adenocarcinoma del colon di stadio III istologicamente confermato, indipendentemente dall'EGFR,
- Resezione curativa R0 condotta non meno di 28 e non piu' di 56 giorni prima della randomizzazione
- Non essersi sottoposti a precedente chemioterapia
- Non essersi sottoposti a precedente radioterapia addominale o pelvica
- Stato di validita' (WHO performance status): 0 o 1
- Consenso informato scritto, firmato, ottenuto prima di una qualsiasi specifica procedura di screening dello studio
- Uso di misure contraccettive efficaci in pazienti a rischio di gravidanza. |
|
E.4 | Principal exclusion criteria |
Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to study treatment start. Incompletely healed wounds or anticipation of the need for major surgical procedure during the course of the study
Metastatic spread at baseline assessment
Rectal cancer located within 15 cm from the anal verge by endoscopy or under the peritoneal reflection at surgery or having received radiation therapy prior to surgery
Presence of inflammatory bowel disease
Known hypersensitivity reaction to any of the components of study treatments
Pregnancy (absence to be confirmed by ß-hCG test) or breast-feeding period
Clinically relevant coronary artery disease or history of myocardial infarction in the last 12 months, or high risk of uncontrolled arrhythmia
Previous malignancy other than CRC in the last 5 years except basal cell carcinoma of the skin and/or in situ carcinoma of the cervix
Medical, geographical, sociological, psychological or legal conditions that would not permit the patient to complete the study or sign informed consent
History or current evidence on physical examination of central nervous system disease or peripheral neuropathy ≥ grade 1 Common Toxicity Criteria for Adverse Events (CTCAE) v.3.0
Any significant disease which, in the investigator's opinion, would exclude the patient from the study |
- Malattia metastatica diffusa
- Malattia infiammatoria intestinale
- Carcinoma del retto localizzato entro 15 cm dal margine anale mediante endoscopia oppure sotto la riflessione peritoneale all'intervento chirurgico, o che sia stato trattato con radioterapia prima dell'operazione
- Donne in stato di gravidanza o in allattamento
- Neuropatia
- Reazione di ipersensibilita' nota nei confronti di uno qualsiasi dei componenti del trattamento oggetto di studio. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary target variable is disease free survival (DFS). DFS is defined as the interval from randomization to locoregional or metastatic recurrence or the appearance of a secondary colorectal cancer or death, whichever occurs first. Patients who are alive and without recurrence or secondary colorectal cancer at the time of cut-off will be right-censored at the most recent date of assessment. Recurrence may be either histologically proven or evidenced by imaging. Isolated CEA elevation will not be sufficient to determine a relapse |
The primary target variable is disease free survival (DFS). DFS is defined as the interval from randomization to locoregional or metastatic recurrence or the appearance of a secondary colorectal cancer or death, whichever occurs first. Patients who are alive and without recurrence or secondary colorectal cancer at the time of cut-off will be right-censored at the most recent date of assessment. Recurrence may be either histologically proven or evidenced by imaging. Isolated CEA elevation will not be sufficient to determine a relapse |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 43 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the study treatment period is defined as 30 days after the last patient has received the last treatment administration.
Study discontinuation:
Medical or ethical reasons or Difficulties in the recruitment |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 9 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 9 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |